Ilsung Pharmaceuticals Co., Ltd.

KRX:003120.KS

25300 (KRW) • At close July 1, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

202420232022202120202019201820172016201520142013201220112010200920082007
Revenue 69,018.34178,053.23261,247.84742,089.83640,600.73248,411.62861,652.59567,043.03567,463.38461,745.11662,828.92162,807.4977,160.76168,191.77568,594.69371,467.21479,870.40478,833.528
Cost of Revenue 41,969.6543,337.40733,312.70925,954.75527,418.60530,246.26639,059.00340,798.90842,473.7439,584.13341,508.31741,725.42455,893.80243,732.57744,087.6140,698.61342,842.19637,028.404
Gross Profit 27,048.69134,715.82527,935.13816,135.08113,182.12818,165.36222,593.59226,244.12724,989.64422,160.98321,320.60321,082.06621,266.95924,459.19824,507.08330,768.60137,028.20841,805.124
Gross Profit Ratio 0.3920.4450.4560.3830.3250.3750.3660.3910.370.3590.3390.3360.2760.3590.3570.4310.4640.53
Reseach & Development Expenses 354.361,523.6891,512.38499.083109.2193.488131.815303.957237.142318.931212.553417.762881.3311,070.1711,167.7591,117.025544.196415.478
General & Administrative Expenses 2,262.3822,614.3751,606.7761,478.3211,405.3021,629.4542,079.7332,339.9512,747.5062,689.122,907.2842,776.6512,776.7812,503.5642,378.2942,314.772,517.9072,998.271
Selling & Marketing Expenses 20,804.31420,166.3613,174.3417,669.8884,576.6577,608.0687,885.10810,488.7399,090.8226,709.2225,816.4816,366.7445,556.1896,596.9476,476.5786,124.7935,682.4716,470.976
SG&A 23,066.69640,948.18914,781.1179,148.2095,981.9599,237.5229,964.84112,828.6911,838.3289,398.3428,723.7659,143.3958,332.979,100.5118,854.8728,439.5638,200.3789,469.247
Other Expenses 13,145.743010,344.3788,685.29,038.74310,091.47-343.243147.476-226.874124,653.48894.3648,539.03147,047.88642,547.877173.555310.781421.3442,536.162
Operating Expenses 36,566.79942,471.87826,637.87917,932.49215,129.91219,422.4820,335.23723,653.71722,535.19619,571.42218,889.92919,710.08519,946.83520,223.7220,019.15618,633.59718,793.24121,353.257
Operating Income -9,518.107-7,756.053140,224.6751,628.334-298.556226.7672,258.3552,590.412,454.4482,589.5612,430.6741,371.9811,320.1244,470.464,487.92712,135.00418,234.96820,451.867
Operating Income Ratio -0.138-0.0992.2890.039-0.0070.0050.0370.0390.0360.0420.0390.0220.0170.0660.0650.170.2280.259
Total Other Income Expenses Net 20,680.761-13,588.8832,071.409-1,067.26,364.70410,436.262,328.4061,991.7961,553.14128,429.7435,476.0479,603.59546,974.71742,508.2034,586.655-627.99729,883.5285,665.275
Income Before Tax 11,162.653-21,344.936137,972.862-1,523.3334,416.9179,179.1434,586.7614,582.2064,987.443131,019.3057,906.72210,975.57648,294.84146,978.6639,074.58211,507.00748,118.49626,117.142
Income Before Tax Ratio 0.162-0.2732.253-0.0360.1090.190.0740.0680.0742.1220.1260.1750.6260.6890.1320.1610.6020.331
Income Tax Expense -1,931.454-404.04332,731.67-155.8221,196.6612,460.5931,641.2321,953.5531,970.20132,165.3743,872.1583,020.55811,843.10511,895.6562,777.1173,457.2213,955.4378,417.294
Net Income 13,094.107-20,940.893108,669.346-1,367.513,220.2576,718.552,945.5292,628.6533,017.24298,853.9314,034.5647,955.01836,451.73635,083.0076,297.4658,049.78734,163.05917,699.848
Net Income Ratio 0.19-0.2681.774-0.0320.0790.1390.0480.0390.0451.6010.0640.1270.4720.5140.0920.1130.4280.225
EPS 1,920.8-2,994.342,906.49-178.32419.91971.73438.4391.244914,713600.41,175.45,2814,824.4740.28432,809.21,340
EPS Diluted 1,920.8-2,994.342,906.49-178.32419.91971.73438.4391.244914,713600.41,175.45,2814,824.4740.28432,809.21,340
EBITDA 14,593.758-18,472.029145,292.5111,563.1391,110.9491,827.7555,271.7075,817.8625,476.0325,351.0365,242.3074,574.11151,669.67650,418.5812,513.49514,875.2452,283.24827,644.767
EBITDA Ratio 0.211-0.2372.3720.0370.0270.0380.0860.0870.0810.0870.0830.0730.670.7390.1820.2080.6550.351